Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Napierala, Marek  [Clear All Filters]
Journal Article
Bhalla AD, Khodadadi-Jamayran A, Li Y, Lynch DR, Napierala M. Deep sequencing of mitochondrial genomes reveals increased mutation load in Friedreich's ataxia. Ann Clin Transl Neurol. 2016;3(7):523-536.
Li J, Rozwadowska N, Clark A, Fil D, Napierala JS, Napierala M. Excision of the expanded GAA repeats corrects cardiomyopathy phenotypes of iPSC-derived Friedreich's ataxia cardiomyocytes. Stem Cell Res. 2019;40:101529.
Butler JSergeskett, Napierala M. Friedreich's ataxia - a case of aberrant transcription termination?. Transcription. 2015.
Libby CJ, Zhang S, Benavides GA, Scott SE, Li Y, Redmann M, Tran ANhat, Otamias A, Darley-Usmar V, Napierala M, et al. Identification of Compounds That Decrease Glioblastoma Growth and Glucose Uptake in Vitro. ACS Chem Biol. 2018.
Butler JSergeskett, Napierala M. New Reasons to Pursue the Therapeutic Potential of Synthetic Nucleic Acids for Neurological Diseases. JAMA Neurol. 2016.
Williford SE, Libby CJ, Ayokanmbi A, Otamias A, Gordillo JJ, Gordon ER, Cooper SJ, Redmann M, Li Y, Griguer C, et al. Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cells. PLoS One. 2021;16(5):e0250649.
Wang D, Ho ES, M Cotticelli G, Xu P, Napierala JS, Hauser LA, Napierala M, Himes BE, Wilson RB, Lynch DR, et al. Skin fibroblast metabolomic profiling reveals that lipid dysfunction predicts the severity of Friedreich's ataxia. J Lipid Res. 2022:100255.
Li Y, Li J, Wang J, Lynch DR, Shen X, Corey DR, Parekh D, Bhat B, Woo C, Cherry JJ, et al. Targeting 3' and 5' untranslated regions with antisense oligonucleotides to stabilize frataxin mRNA and increase protein expression. Nucleic Acids Res. 2021.